Can a new eyelid balm make eczema treatment kinder to the eyes?
NCT ID NCT07819071
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers are testing whether an investigational eyelid emollient balm improves comfort and tolerance when used with tacrolimus 0.1% ointment in adults with atopic eyelid dermatitis. The study enrolls 33 people aged 18 to 65 with eczema on both eyelids. Each person applies the balm to one eyelid and tacrolimus alone to the other for two weeks, so the two sides can be compared directly. The team measures itching, burning, pain, discomfort, and overall eyelid eczema severity, along with how well each side tolerates the products.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an investigational eyelid emollient balm used alongside tacrolimus 0.1% ointment
- What this could lead to
- If the balm helps, it could offer a gentler way to calm eyelid eczema when used with tacrolimus, possibly reducing stinging and irritation.
- What could go wrong
- This is a small, short study of 33 people over two weeks. Any benefit may be modest, and results may not apply to everyone with eyelid eczema.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
33 people
The number who actually took part.
- Started
-
Nov 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* Female and Male * Subjects from 18 to 65 years old * Subject who has signed his/her written informed consent for his/her participation in the study and a photograph authorization * Subject presenting atopic dermatitis according to the definition of "the U.K Working Party's Diagnostic Criteria for Atopic Dermatitis." * Subjects with Atopic Eyelid Dermatitis with bilateral involvement of similar surface and same intensity (no more than 1 point of difference in the total L-SCORAD) * Subjects with atopic dermatitis flare-up on the eyelids requiring topical calcineurin inhibitor treatment (tacrolimus 0.1%) and initiated within the last 24 hours * Subject who has started a topical calcineurin inhibitor treatment (tacrolimus 0.1%; twice a day) on the eyelids within the last 24 hours prior to the inclusion * Subject who used the same cleansing product on face the same make-up (if applicable) for at least two weeks before inclusion and remain stable during the whole study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centrum Medyczne "Tu Się Leczy" Norwida
Gdansk, Poland, 80280, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.